Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services
FROM:
Jerry McGinty, Director, Legislative Budget Board
IN RE:
SB1820 by Bettencourt (Relating to the promotion of off-label uses of certain drugs, biological products, and devices.), As Introduced
No significant fiscal implication to the State is anticipated.
The bill would authorize a pharmaceutical manufacturer or its representative to promote the off-label use of certain drugs, biological products, and devices, and authorize a physician or health care provider to communicate the off-label use to patients. Relevant state and local government entities would be prohibited from imposing related disciplinary actions or enforcement activities against pharmaceutical manufacturers, physicians, and health care providers. According to the Board of Pharmacy, the Texas Board of Nursing, the Texas Medical Board, and the Department of State Health Services, the provisions of the bill could be implemented using existing resources.
Local Government Impact
No significant fiscal implication to units of local government is anticipated.
Source Agencies:
503 Texas Medical Board, 507 Texas Board of Nursing, 515 Board of Pharmacy, 537 State Health Services